Brief Title
To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC
Official Title
A Retrospective Real-world Study in Patients With Nasopharyngeal Carcinoma: to Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC
Brief Summary
This is a retrospective real-world study to evaluate the efficacy and feasibility of modified reduce-volume target IMRT in the treatment of patients with non-metastatic NPC
Study Type
Observational
Primary Outcome
Local failure-free survival (LFFS)
Condition
Nasopharyngeal Carcinoma
Intervention
modified reduce-volume target IMRT
Study Arms / Comparison Groups
Modified reduce-volume target IMRT
Description: Patients with newly diagnosed, non-metastatic NPC was given modified reduce-volume target IMRT
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Radiation
Estimated Enrollment
471
Start Date
June 1, 2020
Completion Date
October 1, 2020
Primary Completion Date
August 1, 2020
Eligibility Criteria
Inclusion Criteria: 1. Pathologic diagnosis (pathologically confirmed by nasopharyngeal biopsy) was nasopharyngeal carcinoma; 2. Newly diagnosed, non-metastatic and treated with modified reduce-volume IMRT; 3. Patients with baseline MRI date of nasopharynx and neck, and completed the first course of treatment in our hospital; 4. Diagnosis time: November 1, 2014 to December 31 , 2017 Exclusion Criteria: 1. Disease progression during IMRT; 2. Previous malignancy or other concomitant malignant diseases; 3. The evaluation information of tumor efficacy can not be obtained; 4. Receive blind treatment in other clinical research.
Gender
All
Ages
N/A - N/A
Accepts Healthy Volunteers
No
Contacts
, ,
Location Countries
China
Location Countries
China
Administrative Informations
NCT ID
NCT04387266
Organization ID
NPC004
Responsible Party
Sponsor
Study Sponsor
Fujian Cancer Hospital
Study Sponsor
, ,
Verification Date
October 2020